Bulltick Wealth Management LLC Sells 56,571 Shares of Pfizer Inc. (NYSE:PFE)

Bulltick Wealth Management LLC decreased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 39.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 86,061 shares of the biopharmaceutical company's stock after selling 56,571 shares during the quarter. Bulltick Wealth Management LLC's holdings in Pfizer were worth $2,283,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the 4th quarter worth $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer in the 4th quarter worth approximately $28,000. Noble Wealth Management PBC bought a new position in Pfizer in the fourth quarter worth approximately $31,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer during the 4th quarter valued at about $33,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 0.5 %

PFE traded down $0.10 during trading on Wednesday, reaching $22.78. 48,160,808 shares of the stock were exchanged, compared to its average volume of 40,426,421. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock's 50 day moving average price is $24.22 and its two-hundred day moving average price is $25.67. The stock has a market cap of $129.18 billion, a P/E ratio of 16.15, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the business earned $0.82 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.55%. Pfizer's payout ratio is presently 124.64%.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PFE. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.